

Title (en)

METHODS FOR DETECTION OF KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS-LIKE VIRUS

Title (de)

VERFAHREN ZUR DETEKTION EINES KAPOSI-SARKOM-ASSOZIERTEN-HERPESVIRUS-ÄHNLICHEN VIRUS

Title (fr)

METHODES DE DETECTION D'UN VIRUS SEMBLABLE A L'HERPESVIRUS ASSOCIE AU SARCOMME DE KAPOSI

Publication

EP 0967983 A2 20000105 (EN)

Application

EP 98906414 A 19980212

Priority

- US 9802820 W 19980212
- US 80071097 A 19970214
- US 96750497 A 19971111

Abstract (en)

[origin: WO9835684A2] The present invention discloses methods for the detection and identification of Kaposi's sarcoma-associated herpesvirus-like Virus (KSHV)-specific nucleic acid sequences or proteins in biological samples derived from patients diagnosed with multiple myeloma (MM) or monoclonal gammopathy of undetermined significance (MGUS). KSHV-specific nucleic acid sequences are detected in these patients by the utilization of polymerase chain reaction (PCR) or reverse transcription polymerase chain reaction (RT-PCR) to amplify viral-specific sequences indigenous to the tissue/cells of these aforementioned patients. The present invention also discloses several methods for the prophylactic and/or therapeutic treatment of patients with MM or MGUS. Potential treatment modalities disclosed in the present invention include, but are not limited to: (1) the use of inhibitory nucleic acids (INAs), such as "anti-sense" oligonucleotides, to inhibit various viral processes (e.g., DNA replication, mRNA transcription, and/or protein translation); (2) the use of viral-specific polyclonal or monoclonal antibodies, or biologically-active fragments or derivatives thereof, the binding of which may be used to inhibit initial viral infection, replicative/protein synthetic processes, or for the "delivery" of anti-viral agents conjugated to a portion of the immunoglobulin; (3) the utilization of systemic anti-viral chemotherapeutic agents which inhibit viral infection or replicative/protein synthetic processes; and/or (4) the use of a KSHV-specific vaccine to inoculate individuals and elicit a prophylactic or therapeutic immune responses through the utilization of KSHV-specific nucleic acid sequences or recombinant proteins as inoculates to elicit such immune response(s).

IPC 1-7

A61K 31/70; **A61K 39/00**; **A61K 39/395**; **C12Q 1/68**

IPC 8 full level

A61K 39/245 (2006.01); **C07K 14/03** (2006.01); **A61K 38/00** (2006.01)

CPC (source: EP)

A61K 39/12 (2013.01); **A61K 39/245** (2013.01); **A61K 47/55** (2017.07); **C07K 14/005** (2013.01); **A61K 38/00** (2013.01); **C12N 2710/16422** (2013.01); **C12N 2710/16434** (2013.01)

Citation (search report)

See references of WO 9835684A2

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9835684 A2 19980820; **WO 9835684 A3 19981203**; AU 6164498 A 19980908; CA 2284093 A1 19980820; EP 0967983 A2 20000105

DOCDB simple family (application)

US 9802820 W 19980212; AU 6164498 A 19980212; CA 2284093 A 19980212; EP 98906414 A 19980212